Background:

Dual mobility components in total hip arthroplasty have been successfully in use in Europe for greater than 25 years. However, these implants have only recently obtained FDA approval and acceptance among North American arthroplasty surgeons. Both decreased dislocation rate and decreased wear rates have been proposed benefits of dual mobility components. These components have been used for primary total hip arthroplasty in patients at high risk for dislocation, total hip arthroplasty in the setting of femoral neck fracture, revision for hip instability, and revision for large metal-on-metal (MoM) hip articulation. The literature for the North American experience is lacking.